NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free RVPH Stock Alerts $3.78 -0.12 (-3.08%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$3.44▼$3.9250-Day Range$2.76▼$4.7052-Week Range$2.67▼$9.25Volume564,449 shsAverage Volume338,323 shsMarket Capitalization$105.54 millionP/E RatioN/ADividend YieldN/APrice Target$16.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Reviva Pharmaceuticals alerts: Email Address Reviva Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside343.1% Upside$16.75 Price TargetShort InterestHealthy2.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.15Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.54) to ($0.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.52 out of 5 starsMedical Sector346th out of 938 stocksPharmaceutical Preparations Industry152nd out of 417 stocks 3.5 Analyst's Opinion Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.75, Reviva Pharmaceuticals has a forecasted upside of 343.1% from its current price of $3.78.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.33% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently decreased by 24.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RVPH. Previous Next 2.3 News and Social Media Coverage News SentimentReviva Pharmaceuticals has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search Interest3 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.83% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.54) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReviva Pharmaceuticals has a P/B Ratio of 6.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.Read More RVPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RVPH Stock News HeadlinesMarch 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 27, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual MeetingMarch 26, 2024 | americanbankingnews.comReviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at HC WainwrightMarch 25, 2024 | markets.businessinsider.comOptimistic Buy Rating for Reviva Pharmaceuticals Based on Brilaroxazine’s Broad Therapeutic PromiseMarch 14, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 putMarch 11, 2024 | globenewswire.comReviva to Present at the UBS Virtual CNS DayMarch 29, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 7, 2024 | globenewswire.comReviva to Present at the 36th Annual ROTH ConferenceMarch 3, 2024 | finance.yahoo.comRVPH Mar 2024 3.500 callFebruary 29, 2024 | finance.yahoo.comRVPH Jan 2026 5.500 callFebruary 27, 2024 | finance.yahoo.comRVPH Apr 2024 12.500 callFebruary 23, 2024 | ca.finance.yahoo.comRVPH Mar 2024 4.500 putFebruary 22, 2024 | benzinga.comReviva Pharmaceuticals Stock (NASDAQ:RVPH), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comReviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor ConferenceFebruary 17, 2024 | finance.yahoo.comRVPH Mar 2024 3.000 callFebruary 17, 2024 | finance.yahoo.comRVPH Mar 2024 5.500 putJanuary 25, 2024 | finance.yahoo.comReviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select ConferenceJanuary 17, 2024 | ca.finance.yahoo.comRVPH Jan 2025 7.500 callJanuary 10, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva to Present at Webull LIVE! Healthcare Webinar on January 17January 10, 2024 | finance.yahoo.comReviva to Present at Webull LIVE! Healthcare Webinar on January 17January 4, 2024 | finance.yahoo.comReviva Provides Corporate and Program Updates and Highlights Key Upcoming MilestonesDecember 28, 2023 | benzinga.comReviva Pharmaceuticals Stock (NASDAQ:RVPH) Dividends: History, Yield and DatesDecember 26, 2023 | finance.yahoo.comKaruna downgraded, Arm target raised: Wall Street's top analyst callsDecember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alector (ALEC), Reviva Pharmaceuticals Holdings (RVPH) and Oculis Holding (OCS)See More Headlines Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Next Earnings (Estimated)4/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$16.75 High Stock Price Target$20.00 Low Stock Price Target$12.00 Potential Upside/Downside+343.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,344.46% Return on Assets-307.04% Debt Debt-to-Equity RatioN/A Current Ratio0.41 Quick Ratio0.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book6.30Miscellaneous Outstanding Shares27,919,000Free Float19,032,000Market Cap$105.53 million OptionableOptionable Beta-0.02 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Laxminarayan Bhat Ph.D. (Age 59)Founder, CEO, President & Director Comp: $560kMr. Narayan Prabhu (Age 52)Chief Financial Officer Comp: $412.5kKey CompetitorsLantern PharmaNASDAQ:LTRNCyteir TherapeuticsNASDAQ:CYTTVincerx PharmaNASDAQ:VINCOramed PharmaceuticalsNASDAQ:ORMPDiaMedica TherapeuticsNASDAQ:DMACView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 359,050 shares on 3/11/2024Ownership: 3.492%Virtu Financial LLCBought 15,234 shares on 2/26/2024Ownership: 0.055%Citadel Advisors LLCSold 62,600 shares on 2/15/2024Ownership: 0.000%Torno Capital LLCBought 10,000 shares on 2/15/2024Ownership: 0.000%GTS Securities LLCSold 12,100 shares on 2/15/2024Ownership: 0.000%View All Institutional Transactions RVPH Stock Analysis - Frequently Asked Questions Should I buy or sell Reviva Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares. View RVPH analyst ratings or view top-rated stocks. What is Reviva Pharmaceuticals' stock price target for 2024? 4 Wall Street research analysts have issued 12 month price objectives for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $16.75 in the next year. This suggests a possible upside of 343.1% from the stock's current price. View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts. How have RVPH shares performed in 2024? Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH stock has decreased by 26.6% and is now trading at $3.78. View the best growth stocks for 2024 here. When is Reviva Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our RVPH earnings forecast. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) issued its earnings results on Monday, November, 15th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.11. Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (6.32%), Vanguard Group Inc. (3.49%), Vanguard Group Inc. (3.49%), Citadel Advisors LLC (0.00%), Northern Trust Corp (0.14%) and Tower Research Capital LLC TRC (0.14%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RVPH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.